Pharmaceutical Intermediates
Full official intermediate catalog + key intermediates with CEP / DMF / GMP / cold-chain qualifications and capacity details · each quotable via RFQ
Featured ProductsProven track record · documents on request
Enter hub →Orforglipron intermediates
Sample orders (500 g each) + 0.5 kg repeat order
Dealt 1–4 · latest 2026-09
Documents in progress
PINACOLONE
Dual-use item (trade control category)
Dealt 1–4 · latest 2026-01
Documents in progress
4-(3-Bromophenyl)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinoline
CAS 543737-10-6
Dealt 1–4 · latest 2026-07
Documents in progress
L-Tyrosine disodium salt, dihydrate
100–199 deals · latest 2026-09
Open for inquiry →
D-Glucose Anhydrous
100–199 deals · latest 2026-09
Open for inquiry →
Choline chloride
CAS 67-48-1
100–199 deals · latest 2026-09
Open for inquiry →
2026 Key Intermediate Campaigns →
4 target drugs · 7 key intermediatesAntiviral (HIV-1)
Metabolic (obesity / type 2 diabetes)
Oncology (breast cancer)
Endocrine (Cushing's syndrome)
Patent-cliff opportunities · recommended intermediates
Ranked by opportunity score · source: patent-cliff radarOpen opportunity profile →semaglutide
68Intermediate list in preparation — inquiries welcome
Key opportunity markets: India / Bangladesh / Pakistan
olaparib
66Key opportunity markets: United States / Canada / Mexico
apixaban
62Key opportunity markets: United Kingdom / Germany / Italy
sacubitril/valsartan
62Intermediate list in preparation — inquiries welcome
Key opportunity markets: China / Japan / South Korea
tirzepatide
61Key opportunity markets: China / Japan / South Korea
sacubitril/valsartan
61Intermediate list in preparation — inquiries welcome
Key opportunity markets: United States / Canada / Mexico
Region is inferred coarsely from your browser IP (region-level only, IP not stored). Opportunity scores are internal radar ratings, not a commitment.
By Therapeutic Area of Target Drug
Click a class to filter both sections below; classes follow the target API's primary indicationDiabetes, obesity, dyslipidemia, NASH and other metabolic diseases
Hypertension, heart failure, anticoagulation, chronic kidney disease
Solid tumours, haematologic malignancies, myeloproliferative diseases
Antiviral, antibacterial, antifungal, HIV / hepatitis
RA, psoriasis, atopic dermatitis, IBD
Epilepsy, pain, depression & anxiety, neurodegeneration
Acid-related, GI motility, diarrhoea, liver disease
COPD, asthma and other airway diseases
Menopausal symptoms, urological conditions
Glaucoma, ocular surface disease
Skin infection, dermatologic inflammation
Local anaesthesia, postoperative analgesia
Allergic rhinitis, urticaria
Companion-animal ectoparasiticides
Qualified Key IntermediatesCEP / DMF / GMP / Cold-chain / Capacity / Price-band details
13 items| Product / CAS | Purity / Impurity profile (redacted) | Synthesis route (redacted) | Capacity | Qualifications | Packaging / Cold-chain | MOQ / Price band | Action |
|---|---|---|---|---|---|---|---|
Lenacapavir INT-1 | N-Boc chiral amine ester CAS 1620056-47-4 · Antivirals Target drug: lenacapavir Highly confidential | ≥99.0% Single impurity ≤0.10%, total impurities ≤0.50% (redacted) | chiral reduction + Boc protection (redacted summary) | 1,200 kg/yr | US DMF | 5 kg / 25 kg drum (aluminium foil bag liner) | 1 kg US$ 2,600-3,800 / kg | Unibest Nantong cGMP Site |
Lenacapavir INT-2 | 4- chloro -7- boronate indazole CAS 2189684-53-3 · Antivirals Target drug: lenacapavir Highly confidential | ≥98.5% Related-substance profile available in the CDA data room | indazole construction + Miyaura borylation (redacted summary) | 900 kg/yr | US DMF | 1 kg / 5 kg aluminium bottle Cold chain | 0.5 kg US$ 4,200-6,000 / kg | Unibest Nantong cGMP Site |
Lenacapavir INT-3 | cyclopropane-fused cyclopentane pyrazole acetic acid CAS 1620056-83-8 · Antivirals Target drug: lenacapavir Highly confidential | ≥99.0% Chiral purity ≥99.5% ee (redacted) | bicyclic construction + trifluoromethylation (redacted summary) | 700 kg/yr | US DMF | 1 kg aluminium bottle Cold chain | 0.5 kg US$ 5,800-8,200 / kg | Unibest Nantong cGMP Site |
Lenacapavir INT-4 | 3- methyl -3-(methanesulfonyl)-1- butyne CAS 2109226-54-0 · Antivirals Target drug: lenacapavir Visible after CDA | ≥98.0% Single impurity ≤0.20% (redacted) | alkynylation + sulfone introduction (redacted summary) | 2,400 kg/yr | 25 kg drum | 5 kg US$ 780-1,150 / kg | Unibest Taizhou GMP-like Site | |
Lenacapavir (GS-6207) API CAS 2189684-44-2 · Antivirals Target drug: lenacapavir Highly confidential | ≥99.5% Single impurity ≤0.10%, total impurities ≤0.30% (redacted) | convergent coupling + salt formation (redacted summary) | 300 kg/yr | US DMFEU GMP | 100 g / 1 kg aluminium bottle (closed system) Cold chain | 100 g 🔒 Available after CDA | Unibest Nantong cGMP Site |
Doravirine INT-1 | 3- chloro -5-[(pyridyl) oxy] benzonitrile CAS 1155846-86-8 · Antivirals Target drug: doravirine Visible after CDA | ≥99.0% Single impurity ≤0.15% (redacted) | aromatic nucleophilic substitution ether formation (redacted summary) | 3,600 kg/yr | US DMFEU GMP | 25 kg drum | 10 kg US$ 420-620 / kg | Qualified Partner — East China API Works |
Doravirine INT-2 | 3- chloro -5- iodophenol CAS 861347-86-6 · Antivirals Target drug: doravirine | ≥99.0% Single impurity ≤0.15% (redacted) | selective iodination (redacted summary) | 5,200 kg/yr | 25 kg drum | 25 kg US$ 210-320 / kg | Qualified Partner — East China API Works | |
Entecavir INT-1 | purine nucleoside intermediate CAS 142217-80-9 · Antivirals Target drug: entecavir | ≥99.0% Single impurity ≤0.10% (redacted) | glycosylation + protecting-group strategy (redacted summary) | 1,800 kg/yr | CEPUS DMFEU GMP | 5 kg / 25 kg drum | 5 kg US$ 1,150-1,700 / kg | Qualified Partner — East China API Works |
Belzutifan INT-1 | (R)-3- fluoro -5-[(indanonyl) oxy] benzonitrile CAS 2738675-96-0 · Anti-cancer Target drug: belzutifan Highly confidential | ≥99.0% Chiral purity ≥99.5% ee (redacted) | chiral reduction + ether formation (redacted summary) | 800 kg/yr | US DMF | 1 kg / 5 kg aluminium bottle | 1 kg US$ 3,400-4,900 / kg | Unibest Taizhou GMP-like Site |
Belzutifan INT-2 | 3-[(indanonyl) oxy]-5- fluoro benzonitrile CAS 1672665-55-2 · Anti-cancer Target drug: belzutifan Highly confidential | ≥99.0% Single impurity ≤0.10% (redacted) | ether formation + sulfone oxidation (redacted summary) | 1,100 kg/yr | 5 kg drum | 2 kg US$ 2,100-3,100 / kg | Unibest Taizhou GMP-like Site | |
2'-dG(iBu) phosphoramidite monomer CAS 68892-42-2 · Nucleic Acids Target drug: oligonucleotide | ≥99.0% Single impurity ≤0.10% (redacted) | nucleoside protection + phosphitylation (redacted summary) | 400 kg/yr | US DMFEU GMP | 100 g / 1 kg aluminium bottle Cold chain | 100 g US$ 1,600-2,400 / 100g | Unibest Nantong cGMP Site |
2'-dA(Bz) phosphoramidite monomer CAS 4546-72-9 · Nucleic Acids Target drug: oligonucleotide | ≥99.0% Single impurity ≤0.10% (redacted) | nucleoside protection + phosphitylation (redacted summary) | 400 kg/yr | US DMFEU GMP | 100 g / 1 kg aluminium bottle Cold chain | 100 g US$ 1,480-2,200 / 100g | Unibest Nantong cGMP Site |
2'-dC(Bz) phosphoramidite monomer CAS 4836-13-9 · Nucleic Acids Target drug: oligonucleotide | ≥99.0% Single impurity ≤0.10% (redacted) | nucleoside protection + phosphitylation (redacted summary) | 350 kg/yr | US DMFEU GMP | 100 g / 1 kg aluminium bottle Cold chain | 100 g US$ 1,520-2,280 / 100g | Unibest Nantong cGMP Site |